Back to Search
Start Over
Therapeutic potential of oncolytic Newcastle disease virus a critical review
- Source :
- Oncolytic Virotherapy, Vol 2015, Iss Issue 1, Pp 49-62 (2015)
- Publication Year :
- 2015
- Publisher :
- Dove Medical Press, 2015.
-
Abstract
- Shay Tayeb,1,2 Zichria Zakay-Rones,2 Amos Panet21Department of Biotechnology, Hadassah Academic College, Jerusalem, Israel; 2Department of Biochemistry and Molecular Biology, The Chanock Center for Virology, Institute of Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, IsraelAbstract: Newcastle disease virus (NDV) features a natural preference for replication in many tumor cells compared with normal cells. The observed antitumor effect of NDV appears to be a result of both selective killing of tumor cells and induction of immune responses. Genetic manipulations to change viral tropism and arming the virus with genes encoding for cytokines improved the oncolytic capacity of NDV. Several intracellular proteins in tumor cells, including antiapoptotic proteins (Livin) and oncogenic proteins (H-Ras), are relevant for the oncolytic activity of NDV. Defects in the interferon system, found in some tumor cells, also contribute to the oncolytic selectivity of NDV. Notwithstanding, NDV displays effective oncolytic activity in many tumor types, despite having intact interferon signaling. Taken together, several cellular systems appear to dictate the selective oncolytic activity of NDV. Some barriers, such as neutralizing antibodies elicited during NDV treatment and the extracellular matrix in tumor tissue appear to interfere with spread of NDV and reduce oncolysis. To further understand the oncolytic activity of NDV, we compared two NDV strains, ie, an attenuated virus (NDV-HUJ) and a pathogenic virus (NDV-MTH-68/H). Significant differences in amino acid sequence were noted in several viral proteins, including the fusion precursor (F0) glycoprotein, an important determinant of replication and pathogenicity. However, no difference in the oncolytic activity of the two strains was noted using human tumor tissues maintained as organ cultures or in mouse tumor models. To optimize virotherapy in clinical trials, we describe here a unique organ culture methodology, using a biopsy taken from a patient's tumor before treatment for ex vivo infection with NDV to determine the oncolytic potential on an individual basis. In conclusion, oncolytic NDV is an excellent candidate for cancer therapy, but more knowledge is needed to ensure success in clinical trials.Keywords: Newcastle disease virus, NDV-HUJ, oncolysis, immunotherapy, models
Details
- Language :
- English
- ISSN :
- 22531572
- Volume :
- 2015
- Database :
- OpenAIRE
- Journal :
- Oncolytic Virotherapy
- Accession number :
- edsair.doajarticles..abc1f7e6286bd47354a5b448cf4ce2f2